Bleomycin hydrochloride 

Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic^[1].

Bleomycin hydrochloride is chosen as the best-studied micronucleus inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation^[1].
The IC₅₀ value of Bleomycin hydrochloride for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin; IC₅₀ values are 14.2±2.8 nM and 13.0±1.1 nM, respectively^[2].
Bleomycin hydrochloride (50, 100 μM; for 24, 48 h) induce pulmonary fibrosis in RLE-6TN cell (50 μM) and A549 cell (100 μM)^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bleomycin hydrochloride treatment (3.5-4.0 mg/kg; intra-tracheal) on day 0, body weights decreases by day 4 then increases by Day 7 through the end of the study^[3].
Bleomycin hydrochloride (3.5-4.0 mg/kg; intra-tracheal) produces a statistically significant increase in lung hydroxyproline levels, and also increases right caudal lung lobe mass^[3].
Bleomycin hydrochloride (intratracheal instillation; 5.0 mg/kg/day) induces pulmonary fibrosis in eighty 8-week-old male BALB/c mice with weight about 20-30 g. Bleomycin induces the expression levels of α-SMA and collagen I^[4].
Bleomycin hydrochloride (intratracheally; 2.5 mg/kg; 1.25 mg/ml, approximately 50 µl per mouse) induces pulmonary fibrosis in male C57BL/6 mice (8 weeks old, average weight approximately 24.5 g)^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Solid

67763-87-5

O=C(C1=NC([[email protected]](CC(N)=O)NC[[email protected]](N)C(N)=O)=NC(N)=C1C)N[[email protected]](C(N[[email protected]](C)[[email protected]@H](O)[[email protected]](C)C(N[[email protected]]([[email protected]](O)C)([H])C(NCCC2=NC(C3=NC(C(N[R])=O)=CS3)=CS2)=O)=O)=O)[[email protected]](C4=CN=CN4)O[[email protected]]5[[email protected]]([[email protected]]([[email protected]@H]([[email protected]@H](O5)CO)O)O)O[[email protected]]6([H])[[email protected]]([[email protected]]([[email protected]@H]([[email protected]](O6)CO)O)OC(N)=O)O.NC(NCCCC[R])=N.[R]CCC[S+](C)C.[H]Cl.[R=].[Bleomycin A2].[R=].[Bleomycin B2]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

• [1]. Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49.  [Content Brief]

  [2]. Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4.  [Content Brief]

  [3]. Corboz MR, et al. Therapeutic administration of inhaled INS1009, a LRX-15 prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103.  [Content Brief]

  [4]. Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.  [Content Brief]

  [5]. Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978.  [Content Brief]